CDV

Canine distemper virus (CDV) is a highly contagious and potentially fatal viral disease caused by a paramyxovirus of the genus Morbillivirus, closely related to the measles virus in humans and rinderpest virus in cattle. CDV is one of the most significant infectious diseases affecting domestic dogs worldwide and remains a leading cause of infectious disease-related death in unvaccinated dog populations. The virus attacks multiple organ systems simultaneously, including the respiratory tract, gastrointestinal system, central nervous system, and epithelial tissues.

The distemper virus is an enveloped, single-stranded RNA virus that is relatively fragile in the external environment. It is readily inactivated by heat, drying, sunlight, and most common disinfectants, and typically survives outside the host for only a few hours under normal environmental conditions. Despite this environmental fragility, CDV maintains itself in dog populations through efficient respiratory transmission and its ability to infect a broad range of carnivore species that serve as wildlife reservoirs.

CDV has a worldwide distribution, though its prevalence varies significantly based on vaccination coverage and population management practices. In regions with robust vaccination programs, clinical distemper is relatively uncommon in pet dog populations, though outbreaks continue to occur in shelters, rescue operations, and among stray or feral dog populations with low vaccination rates. In many developing countries where vaccination coverage is limited, CDV remains endemic and is a major cause of canine morbidity and mortality.

Beyond domestic dogs, CDV affects a wide range of carnivore species including wolves, coyotes, foxes, raccoons, skunks, ferrets, mink, lions, tigers, and seals. These wildlife species serve as reservoirs for the virus and can transmit it to unvaccinated domestic dogs through direct or indirect contact. The broad host range of CDV contributes to its persistence in the environment and complicates eradication efforts, as vaccination of domestic dogs alone cannot eliminate the virus from wildlife populations.

CDV is primarily transmitted through aerosol droplets expelled during coughing, sneezing, and vocalization by infected animals. The virus is shed in respiratory secretions, and close contact between an infected and susceptible dog is the most efficient mode of transmission. Inhalation of virus-laden aerosol particles allows the virus to deposit on the mucosal surfaces of the upper respiratory tract, where initial infection and replication begin.

In addition to respiratory aerosols, CDV is shed in virtually all body secretions and excretions of infected animals, including nasal and ocular discharge, saliva, urine, and feces. Fomite transmission through contaminated food bowls, bedding, clothing, and equipment is possible but less common due to the virus's environmental fragility. Transplacental transmission from an infected dam to her puppies can occur, potentially resulting in neonatal infection, abortion, or stillbirth.

Following inhalation, the virus initially infects and replicates in tissue macrophages and lymphocytes in the respiratory-associated lymphoid tissue. Within 24 hours, infected macrophages transport the virus to regional lymph nodes, initiating a cell-associated viremia that disseminates the virus throughout the body. By days two through six post-infection, the virus has spread to the tonsils, retropharyngeal lymph nodes, bronchial lymph nodes, thymus, spleen, and bone marrow, resulting in widespread lymphoid tissue infection and profound immunosuppression.

The outcome of CDV infection is largely determined by the host's immune response. Dogs that mount a strong humoral and cell-mediated immune response by days 9 to 14 post-infection can clear the virus and recover, often with mild or subclinical disease. Dogs with an intermediate or weak immune response experience viral spread to epithelial tissues throughout the body, including the respiratory epithelium, gastrointestinal mucosa, urogenital epithelium, skin, and critically, the central nervous system. This widespread epithelial infection produces the multisystemic clinical signs characteristic of canine distemper. The immunosuppression caused by CDV also predisposes infected dogs to secondary bacterial infections, which often contribute significantly to morbidity and mortality.

The clinical presentation of CDV is highly variable and reflects the virus's ability to infect multiple organ systems. The incubation period is typically one to two weeks, though it can range from several days to five weeks. Early clinical signs are often subtle and nonspecific, beginning with a transient fever spike that may go unnoticed by owners. This initial febrile episode corresponds to the early viremic phase and is followed by a brief period of apparent improvement before the onset of more recognizable clinical disease.

Respiratory signs are usually the first prominent clinical manifestation and include serous to mucopurulent nasal discharge, sneezing, coughing, and progressive dyspnea. Secondary bacterial pneumonia frequently complicates the viral respiratory infection, producing more severe coughing, increased respiratory rate, labored breathing, and purulent nasal discharge. Ocular signs typically accompany the respiratory phase and include bilateral conjunctivitis with serous to mucopurulent ocular discharge. In some cases, keratoconjunctivitis sicca (dry eye) develops due to viral damage to the lacrimal glands, and anterior uveitis or optic neuritis may occur.

Gastrointestinal signs develop concurrently with or shortly after respiratory signs and include anorexia, vomiting, and diarrhea that may range from mild and watery to severe and hemorrhagic. The combination of respiratory and gastrointestinal disease, along with immunosuppression, results in significant debilitation, weight loss, and dehydration. Puppies and young dogs are particularly vulnerable to the catabolic effects of concurrent vomiting, diarrhea, and reduced food intake.

Neurological signs represent the most devastating aspect of CDV infection and may develop during the acute illness or weeks to months after apparent recovery from systemic disease. Neurological manifestations vary depending on the region of the central nervous system affected and include myoclonus (rhythmic muscle twitching, particularly of the muscles of mastication and limbs), seizures, circling, head tilt, nystagmus, ataxia, paresis or paralysis, and behavioral changes. Hyperesthesia, vestibular dysfunction, and progressive dementia may also occur. The classic canine distemper myoclonus, often called chewing gum fits, is a distinctive and pathognomonic sign. Dermatological signs include hyperkeratosis of the footpads (hardpad disease) and nasal planum, as well as pustular dermatitis, particularly in puppies.

Diagnosing CDV can be challenging because the clinical signs overlap with many other infectious and non-infectious conditions, and no single test is universally reliable across all stages of the disease. A presumptive diagnosis is often made based on the combination of signalment (young, unvaccinated or incompletely vaccinated dog), clinical presentation (progressive multisystemic disease involving respiratory, gastrointestinal, and neurological signs), and supporting laboratory findings.

Routine hematology frequently reveals lymphopenia during the early viremic phase, reflecting viral destruction of lymphoid tissue. This lymphopenia is an important early diagnostic clue, particularly in young dogs with compatible clinical signs. Thrombocytopenia may also be present. Serum biochemistry findings are generally nonspecific but may show electrolyte abnormalities secondary to vomiting and diarrhea. Cerebrospinal fluid analysis in dogs with neurological signs may reveal elevated protein concentrations and mild mononuclear pleocytosis, findings consistent with viral encephalitis.

Reverse transcriptase polymerase chain reaction (RT-PCR) is the most sensitive and specific diagnostic method for confirming CDV infection. RT-PCR can detect viral RNA in blood, conjunctival swabs, nasal swabs, urine, cerebrospinal fluid, and tissue samples. Testing of conjunctival or nasal swabs is particularly useful during the early stages of disease when the virus is actively shedding from epithelial surfaces. However, RT-PCR sensitivity may decline in dogs that have mounted a partial immune response and cleared the virus from peripheral tissues, and recently vaccinated dogs may test positive due to detection of vaccine virus.

Serological testing for CDV antibodies has limited diagnostic utility for acute infection because antibody levels may be low or absent in the early stages when immunosuppression is most profound, and vaccination history confounds interpretation. However, detection of CDV-specific IgM antibodies in unvaccinated dogs suggests recent infection. Measurement of antibody levels in cerebrospinal fluid can support a diagnosis of CDV encephalitis. Immunofluorescent antibody testing on conjunctival or nasal epithelial cells can provide rapid results and is moderately specific, though sensitivity varies with the stage of disease. Postmortem histopathological examination revealing characteristic viral inclusion bodies (both intranuclear and intracytoplasmic) in epithelial and neural tissues confirms the diagnosis.

There is no specific antiviral therapy that effectively eliminates CDV from infected dogs, and treatment is therefore primarily supportive and symptomatic. The goals of treatment are to manage clinical signs, support the immune system, prevent and treat secondary bacterial infections, maintain hydration and nutrition, and provide comfort care during the course of the disease. The intensity of treatment depends on the severity of clinical signs and the systems involved.

Aggressive fluid therapy is a cornerstone of treatment for dogs with CDV. Intravenous administration of balanced electrolyte solutions corrects dehydration caused by vomiting, diarrhea, and reduced oral intake, and helps maintain organ perfusion. Electrolyte imbalances, particularly hypokalemia and hypochloremia, should be identified and corrected. Dextrose supplementation may be necessary for hypoglycemic puppies. Antiemetic medications such as maropitant (Cerenia) help control nausea and vomiting, improving the dog's comfort and reducing fluid losses.

Broad-spectrum antibiotic therapy is essential to treat and prevent secondary bacterial infections, which are a major contributor to morbidity and mortality in CDV-infected dogs. The immunosuppression caused by CDV leaves affected dogs highly vulnerable to opportunistic bacterial pathogens, particularly those causing pneumonia. Commonly used antibiotics include amoxicillin-clavulanate, doxycycline, and fluoroquinolones, selected based on the suspected site and type of secondary infection. Nebulization and coupage may be beneficial for dogs with significant lower respiratory tract disease.

Neurological signs are often the most difficult aspect of CDV to manage. Anticonvulsant medications such as phenobarbital, levetiracetam, or potassium bromide are used to control seizures. Myoclonus, unfortunately, tends to be poorly responsive to treatment and may persist indefinitely in surviving dogs. Anti-inflammatory doses of corticosteroids have been used to reduce central nervous system inflammation, though their use is controversial given the underlying immunosuppression caused by CDV, and they are generally reserved for cases with severe, progressive neurological deterioration. Nutritional support through appetite stimulants, assisted feeding, or in severe cases, feeding tubes, is important for maintaining body condition and supporting immune function during the prolonged recovery period.

The prognosis for dogs with CDV is highly variable and depends on the virulence of the viral strain, the age and immune status of the dog, the systems affected, and the timeliness and quality of supportive care. Overall mortality rates for clinically affected dogs are estimated at 50 percent or higher, with significantly higher rates in puppies, unvaccinated dogs, and those with neurological involvement.

Dogs that develop only mild respiratory and gastrointestinal signs and mount an effective immune response may recover fully within two to four weeks with appropriate supportive care. These dogs generally clear the virus completely and develop strong, long-lasting immunity. Some dogs may experience a subclinical or very mild infection that resolves without specific treatment, though they can still shed the virus and pose a transmission risk to other susceptible animals during the active infection period.

The development of neurological signs significantly worsens the prognosis. Dogs with progressive neurological disease, including severe seizures, paralysis, or rapidly advancing encephalitis, carry a poor to grave prognosis, and humane euthanasia is often recommended when neurological deterioration becomes severe and unresponsive to treatment. Even dogs that survive the neurological phase may be left with permanent neurological deficits, including chronic myoclonus, persistent seizure disorders, behavioral changes, or motor dysfunction that significantly impact quality of life.

Old dog encephalitis is a rare, chronic progressive form of CDV-associated encephalomyelitis that occurs in mature, previously vaccinated dogs. It is thought to result from persistent viral infection in the central nervous system and produces slowly progressive neurological decline over weeks to months. The prognosis for old dog encephalitis is invariably poor. Long-term survivors of acute CDV infection should be monitored for the delayed onset of neurological signs, as viral persistence in neural tissue can produce neurological disease weeks, months, or even years after the initial infection appears to have resolved.

Vaccination is the most effective and important tool for preventing canine distemper. The CDV vaccine is a core vaccine recommended for all dogs by veterinary immunology guidelines worldwide. Modified live virus (MLV) vaccines are the most widely used and provide excellent immunogenicity, inducing both humoral and cell-mediated immunity that closely mimics the protection afforded by natural infection and recovery.

The standard vaccination protocol begins with a series of puppy vaccinations starting at 6 to 8 weeks of age, with booster doses administered every 2 to 4 weeks until the puppy reaches 16 weeks of age or older. This serial vaccination schedule is necessary because maternally derived antibodies (MDA), transferred from the dam to puppies through colostrum, can interfere with the puppy's response to vaccination. MDA levels decline at variable rates among individual puppies, creating a vulnerable window during which maternal immunity has waned but vaccine-induced immunity has not yet been established. Extending the final puppy booster to 16 weeks or later helps ensure that vaccination occurs after MDA has declined sufficiently to allow an active immune response.

Following the initial puppy series, a booster vaccination is administered at one year of age, followed by subsequent boosters every three years for the remainder of the dog's life. Current evidence and immunological guidelines support a three-year revaccination interval for CDV, as the modified live virus vaccines produce durable immunity that persists for at least three years and likely much longer in most dogs. Serological titer testing can be used to assess an individual dog's antibody levels and inform decisions about revaccination timing in cases where owners prefer to minimize vaccine administration.

In shelter and rescue environments, vaccination upon intake is a critical disease prevention measure. All dogs entering shelters should receive a CDV-containing vaccine immediately upon admission, regardless of reported vaccination history. In outbreak situations, more frequent vaccination and strict quarantine protocols may be necessary. Reducing population density, improving ventilation, and minimizing stress are important adjunctive measures for preventing distemper outbreaks in communal settings. Isolation of clinically suspect dogs and appropriate barrier nursing precautions help contain viral spread within a facility.

Shelter and rescue environments present unique challenges for CDV prevention and management due to high animal turnover, variable vaccination histories, crowded conditions, and the stress of confinement. These factors create conditions highly favorable for CDV transmission, and distemper outbreaks in shelters can be devastating in both scope and mortality. Shelter medicine protocols must balance aggressive disease prevention with the practical realities of limited resources and high animal volumes.

Intake vaccination is the single most important intervention for preventing CDV in shelter populations. Every dog should receive a modified live virus CDV vaccine at the point of intake, before being housed with other animals. For puppies, vaccination should begin as early as 4 to 6 weeks of age in high-risk shelter settings, with boosters every two weeks until at least 18 to 20 weeks of age. The extended booster schedule in shelters accounts for the high-risk environment and variable maternal antibody interference.

When a CDV case is identified in a shelter, rapid implementation of outbreak response protocols is essential. Confirmed and suspect cases should be immediately isolated from the general population. Exposed but clinically healthy dogs should be quarantined separately, vaccinated if not already current, and monitored for clinical signs for a minimum of two weeks. Housing areas should be thoroughly cleaned and disinfected, and movement of animals and staff between areas should be restricted. Foster-based housing for healthy animals can reduce population density and exposure risk during an outbreak.

Difficult decisions arise regarding the management of CDV-positive dogs in shelter settings. Mildly affected dogs in foster care or isolation may be treated supportively if resources allow, though the prolonged shedding period (typically several weeks) and the risk of neurological complications complicate management decisions. Shelters must weigh the welfare of the individual animal against the risk posed to the broader population and the resources required for extended isolation and treatment. Transparent communication with staff, volunteers, and the public about CDV risks and management decisions helps maintain trust and support during outbreak responses.

Neurological disease is the most feared complication of CDV infection and represents the primary cause of death and euthanasia in affected dogs. CDV has a pronounced tropism for neural tissue, and the virus can invade the central nervous system through multiple pathways, including hematogenous spread across the blood-brain barrier, infection of choroid plexus epithelium, and retrograde axonal transport along cranial nerves, particularly the olfactory nerve.

The neuropathology of CDV encephalomyelitis involves both direct viral cytolysis of neurons and glial cells and immune-mediated demyelination. In the acute phase, viral replication within neural tissue causes direct cellular damage and an acute inflammatory response. The subsequent immune-mediated phase involves demyelination driven by the host's own immune response to viral antigens expressed on the surface of infected glial cells. This dual mechanism of neural damage explains why neurological signs can progress even as the systemic infection resolves and the dog's immune system gains control of viral replication in other tissues.

Myoclonus is the most characteristic neurological sign of CDV and results from a lower motor neuron lesion affecting specific muscle groups. The rhythmic, repetitive contractions typically involve the muscles of the head, limbs, or trunk and persist during sleep, distinguishing them from seizure activity. Myoclonus often becomes permanent in surviving dogs because it results from irreversible damage to specific motor neuron pools. While the condition is not painful, persistent myoclonus can be distressing to both the dog and the owner and may interfere with rest and normal function.

Seizure disorders are another common neurological sequela of CDV and can manifest during the acute illness or develop weeks to months after recovery. CDV-associated seizures may be focal or generalized, and their frequency and severity can vary from occasional mild episodes to status epilepticus requiring emergency intervention. Long-term anticonvulsant therapy is often necessary for dogs with CDV-related seizure disorders. Other permanent neurological deficits may include persistent ataxia, visual impairment, cognitive dysfunction, and behavioral changes. The quality of life for dogs with chronic neurological sequelae must be carefully and compassionately assessed on an individual basis, with ongoing communication between the veterinary team and the owner regarding expectations, management options, and when appropriate, end-of-life considerations.

Canine distemper virus has one of the broadest host ranges of any carnivore pathogen, infecting species across multiple families within the order Carnivora and beyond. This extensive host range has significant implications for disease ecology, conservation biology, and the control of CDV in domestic dog populations. Wildlife species serve as persistent reservoirs of the virus, maintaining it in the environment even when domestic dog vaccination rates are high.

Raccoons are among the most important wildlife reservoirs of CDV in North America and frequently shed the virus during periodic epizootic outbreaks that sweep through raccoon populations. Skunks, foxes, and coyotes are also commonly affected and can transmit the virus to domestic dogs through direct contact or shared environmental spaces. In urban and suburban settings where wildlife and domestic dogs share habitat, the interface between infected wildlife and unvaccinated or incompletely vaccinated dogs creates ongoing transmission risk.

CDV has caused devastating outbreaks in endangered carnivore populations, raising conservation concerns. The virus contributed to the near-extinction of the black-footed ferret, one of North America's most endangered mammals, and has caused mass mortality events in African wild dogs, Ethiopian wolves, and Amur tigers. CDV outbreaks in Serengeti lions in the 1990s and Caspian seals in the 2000s demonstrated the virus's capacity to jump between phylogenetically distant host species, sometimes with catastrophic consequences for vulnerable populations.

The cross-species transmission dynamics of CDV have important implications for domestic dog health. Viral strains circulating in wildlife may differ genetically from vaccine strains, raising questions about the breadth of cross-protection provided by current vaccines. While commercially available MLV vaccines are generally considered to provide adequate protection against diverse field strains, ongoing genetic surveillance of CDV in both domestic and wildlife populations is important for monitoring viral evolution and ensuring continued vaccine efficacy. One Health approaches that integrate veterinary, wildlife, and public health perspectives are essential for understanding and managing the complex epidemiology of CDV across its extensive host range.